HC Wainwright Reaffirms “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC ...
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts
Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.0, a high estimate of $46.00 ...
4D Molecular, FDA agree on phase 3 design for DME candidate
D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising ...
Promising Interim Results Drive ‘Buy’ Rating for 4D Molecular Therapeutics
Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), retaining the price ...
4D Molecular price target lowered to $42 from $46 at BofA
BofA lowered the firm’s price target on 4D Molecular (FDMT) to $42 from $46 on Friday and kept a Buy rating on the shares. The firm notes 4D ...
FierceBiotech4d
4DMT tosses 2 programs, halts funds for 3 others as it zeroes in on latest-stage clinical gene therapy
4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter ...
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical ...
Investing5d
4D Molecular Therapeutics refocuses on key drug candidates
EMERYVILLE, Calif. - 4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage genetic medicines company with a market capitalization of $270 million, has announced a strategic refocusing of its ...
Investing5d
4D Molecular Therapeutics refocuses on key drug candidates
EMERYVILLE, Calif. - 4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage genetic medicines company with a market capitalization of $270 million, has announced a strategic refocusing of its ...
Nasdaq5d
4DMT Prioritizes 4D-150 And 4D-710 Programs, Extends Cash Runway
(RTTNews) - 4D Molecular Therapeutics, Inc. (FDMT), a clinical-stage genetic medicines company, on Friday, announced strategic updates to its pipeline, prioritizing 4D-150 for wet age-related ...